Live Breaking News & Updates on Edgardo Baracchini
Stay updated with breaking news from Edgardo baracchini. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Not for trading, but in connection with the registration of American Depositary Shares, pursuant to the requirements of the Securities and Exchange Commission. Securities registered or to be registered pursuant to Section 12(g) of the Act: None None Indicate the number of outstanding shares of each of the issuer s classes of capital or common stock as of the close of the period covered by the annual report: Title of each class Ordinary Shares, nominal value £0.0025 per Share 131,467,935 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X] ....
CoIMMUNE: CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company s board of directors. Dr. Baracchini brings a wealth of biotechnology industry and financial expertise, as well as significant prior board level experience, to the CoImmune board of directors. Dr. Baracchini has over 25 years of experience in structuring and negotiating research and development partnerships, mergers and acquisitions, and licensing agreements as a biotech industry executive. He has personally negotiated more than 80 business transactions with multinational pharmaceutical firms, biotechnology companies, and prominent universities. He has significant experience in alliance management, strateg ....
24 feb 2021 CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company’s board of directors. Dr. Baracchini brings a wealth of biotechnology industry and financial expertise, as well as significant prior board level experience, to the CoImmune board of directors. Dr. Baracchini has over 25 years of experience in structuring and negotiating research and development partnerships, mergers and acquisitions, and licensing agreements as a biotech industry executive. He has personally negotiated more than 80 business transactions with multinational pharmaceutical firms, biotechnology companies, and prominent universities. He has significant experience in alliance management, ....